Replies to post #483714 on Anavex Life Sciences Corp (AVXL)

[LakeshoreLeo1953]

Where does the 17% come into play?

[boi568]

I agree, although not having the clock stopped would be very significant.

[IhidfromtheX]

I only find this...https://pharmaphorum.com/market-access/emas-strategy-speeding-drug-approvals-eu

[Investor2014]

You might just ask ChatGPT as follows:

Is an accepted EMA MAA most likely to fail clock stop one or clock stop two before being withdrawn?

ChatGPT answer:

When a **Marketing Authorization Application (MAA)** is submitted to the **European Medicines Agency (EMA)**, the review process includes **two "clock stops"** where the sponsor must respond to the EMA’s concerns before proceeding. If an MAA is ultimately withdrawn, the failure point is more likely to occur at **Clock Stop One** rather than Clock Stop Two. Here's why:

### **1. Overview of EMA Review Process**
- **Day 0–120: Initial Review**
- The EMA’s **Committee for Medicinal Products for Human Use (CHMP)** conducts a preliminary assessment.
- By **Day 120**, the CHMP issues a **List of Questions (LoQ)** outlining major concerns.
- At this point, the clock stops (**Clock Stop One**) to allow the applicant to respond.

- **Clock Stop One (3–6 Months)**
- The applicant provides additional data or justifications.
- If the concerns are **serious and unresolved**, the MAA may be **withdrawn** or proceed with reservations.

- **Day 121–180: Second Review Phase**
- The CHMP evaluates the new responses.
- By **Day 180**, if concerns remain, a **List of Outstanding Issues (LoOI)** is issued.
- The clock stops again (**Clock Stop Two**), allowing the applicant to submit further clarifications.

- **Clock Stop Two (1–2 Months)**
- The applicant submits final justifications.
- If concerns persist, a **negative opinion** is issued, and the company may opt for withdrawal before formal rejection.

---

### **2. Why Failure is More Likely at Clock Stop One**
- **Major Deficiencies Identified Early**: If the EMA raises fundamental efficacy, safety, or manufacturing issues in the first round, the applicant may **choose to withdraw rather than continue** if the required data is difficult to generate.
- **Insufficient Data Gaps**: If the **clinical trial results are weak** or **bioequivalence is not demonstrated**, it’s hard to fix this later in the process.
- **Strategic Withdrawals**: Companies may **voluntarily withdraw** their application after Clock Stop One to avoid a formal rejection, which could hurt future re-submissions.

### **3. When Would Failure Happen at Clock Stop Two?**
- **Marginal Issues Remain**: If initial responses were promising but did not fully resolve all concerns, the CHMP may issue **additional questions**.
- **Regulatory Risk Assessment**: If a sponsor believes the CHMP will vote negatively, they might withdraw just before formal rejection at **Day 210**.

### **Conclusion**
An MAA is **most likely to fail at Clock Stop One**, as major issues tend to be identified early. However, failure at **Clock Stop Two** is possible if responses remain insufficient. A company may choose to withdraw at either stage, but **early-stage withdrawals are more common** to avoid a formal negative opinion.

Would you like insights on specific past cases where this has happened?